Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy

FieldValue
dc.contributor.authorBowerman, Melissa
dc.contributor.authorMurray, Lyndsay M
dc.contributor.authorBoyer, Justin G
dc.contributor.authorAnderson, Carrie L
dc.contributor.authorKothary, Rashmi
dc.date.accessioned2015-12-18T10:54:39Z
dc.date.available2015-12-18T10:54:39Z
dc.date.issued2012-03-07
dc.identifier.citationBMC Medicine. 2012 Mar 07;10(1):24
dc.identifier.urihttp://dx.doi.org/10.1186/1741-7015-10-24
dc.identifier.urihttp://hdl.handle.net/10393/33666
dc.description.abstractAbstract Background Spinal muscular atrophy (SMA) is the leading genetic cause of infant death. It is caused by mutations/deletions of the survival motor neuron 1 (SMN1) gene and is typified by the loss of spinal cord motor neurons, muscular atrophy, and in severe cases, death. The SMN protein is ubiquitously expressed and various cellular- and tissue-specific functions have been investigated to explain the specific motor neuron loss in SMA. We have previously shown that the RhoA/Rho kinase (ROCK) pathway is misregulated in cellular and animal SMA models, and that inhibition of ROCK with the chemical Y-27632 significantly increased the lifespan of a mouse model of SMA. In the present study, we evaluated the therapeutic potential of the clinically approved ROCK inhibitor fasudil. Methods Fasudil was administered by oral gavage from post-natal day 3 to 21 at a concentration of 30 mg/kg twice daily. The effects of fasudil on lifespan and SMA pathological hallmarks of the SMA mice were assessed and compared to vehicle-treated mice. For the Kaplan-Meier survival analysis, the log-rank test was used and survival curves were considered significantly different at P < 0.05. For the remaining analyses, the Student's two-tail t test for paired variables and one-way analysis of variance (ANOVA) were used to test for differences between samples and data were considered significantly different at P < 0.05. Results Fasudil significantly improves survival of SMA mice. This dramatic phenotypic improvement is not mediated by an up-regulation of Smn protein or via preservation of motor neurons. However, fasudil administration results in a significant increase in muscle fiber and postsynaptic endplate size, and restores normal expression of markers of skeletal muscle development, suggesting that the beneficial effects of fasudil could be muscle-specific. Conclusions Our work underscores the importance of muscle as a therapeutic target in SMA and highlights the beneficial potential of ROCK inhibitors as a therapeutic strategy for SMA and for other degenerative diseases characterized by muscular atrophy and postsynaptic immaturity.
dc.titleFasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy
dc.typeJournal Article
dc.date.updated2015-12-18T10:54:39Z
dc.language.rfc3066en
dc.rights.holderBowerman et al; licensee BioMed Central Ltd.
CollectionLibre accès - Publications // Open Access - Publications

Files